| Atlas Holistic Health Pllc | |
|
1244 William D Tate Ave, Grapevine, TX 76051-4030 | |
| (817) 416-9800 | |
| Not Available |
| Full Name | Atlas Holistic Health Pllc |
|---|---|
| Type | Facility |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 1244 William D Tate Ave, Grapevine, Texas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134903719 | NPI | - | NPPES |
| Provider Name | Dean L Allen |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1679564025 PECOS PAC ID: 5395735427 Enrollment ID: I20040512001154 |
News Archive
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).
Mitochondria, the tiny structures inside our cells that generate energy, may play a key role in autism spectrum disorders (ASD).
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
› Verified 5 days ago
| Provider Name | Randee M Poortvliet |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1770691891 PECOS PAC ID: 0749259729 Enrollment ID: I20040929000075 |
News Archive
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).
Mitochondria, the tiny structures inside our cells that generate energy, may play a key role in autism spectrum disorders (ASD).
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
› Verified 5 days ago
| Provider Name | Gabriella O Udabor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063769891 PECOS PAC ID: 0244472066 Enrollment ID: I20130807000710 |
News Archive
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).
Mitochondria, the tiny structures inside our cells that generate energy, may play a key role in autism spectrum disorders (ASD).
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Atlas Holistic Health Pllc Po Box 1326, Grapevine, TX 76099-1326 Ph: () - | Atlas Holistic Health Pllc 1244 William D Tate Ave, Grapevine, TX 76051-4030 Ph: (817) 416-9800 |
News Archive
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).
Mitochondria, the tiny structures inside our cells that generate energy, may play a key role in autism spectrum disorders (ASD).
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.
› Verified 5 days ago